FDA proposes excluding GLP-1s from the 503B bulks list
If finalised, outsourcing facilities would lose the pathway for compounding these molecules at scale.
On 30 April 2026 FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list, citing no clinical need for outsourcing facilities to compound them from bulk active ingredient.
Combined with the 2024 and 2025 shortage resolutions, this would close both pathways that permitted industrial-scale compounding. Patient-specific compounding under 503A remains lawful but cannot replicate 503B volume.
This is a proposal, not a final rule, and coverage frequently conflates the two. If you chose a programme partly because it names a 503B partner, ask what its plan is.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement or the clinical review behind a prescription.
Where a development moves a figure we publish, the change is recorded with its date on our methodology page rather than edited in silently.
How to verify this yourself
Regulatory claims should be checked against the agency rather than coverage of the agency. FDA publishes warning letters searchable by company name and a drug shortage database, both free and both more current than any summary.